Iradimed (IRMD) Common Equity (2013 - 2026)

Iradimed (IRMD) has 14 years of Common Equity data on file, last reported at $98.5 million in Q1 2026.

• Quarterly Common Equity rose 9.39% year-over-year to $98.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98.5 million (up 9.39% YoY) and the FY2025 annual result came in at $94.6 million, up 8.98% from the prior year.
• Common Equity improved to $98.5 million in Q1 2026 per IRMD's latest filing, from $94.6 million in the prior quarter.
• Across five years, Common Equity topped out at $98.5 million in Q1 2026 and bottomed at $62.5 million in Q1 2022.
• The 5-year median for Common Equity is $76.1 million (2024), against an average of $79.6 million.
• The widest annual swing landed in 2023, when Common Equity retreated 3.06%; it then rose 21.56% in 2024.
• Tracing IRMD's Common Equity over 5 years: stood at $73.7 million in 2022, then retreated by 3.06% to $71.4 million in 2023, then gained by 21.56% to $86.8 million in 2024, then advanced by 8.98% to $94.6 million in 2025, then rose by 4.12% to $98.5 million in 2026.
• Per Business Quant, the three latest IRMD Common Equity figures stand at $98.5 million (Q1 2026), $94.6 million (Q4 2025), and $98.4 million (Q3 2025).

Peer Comparison